UK markets closed

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
1.0600+0.0100 (+0.95%)
At close: 04:00PM EDT
1.0800 +0.02 (+1.89%)
After hours: 07:55PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
8,945
8,945
14,703
3,896
773
Cost of revenue
671
671
728
1,426
385
Gross profit
8,274
8,274
13,975
2,470
388
Operating expenses
Research development
15,705
15,705
13,987
33,914
12,317
Selling general and administrative
17,302
17,302
22,508
18,212
15,571
Total operating expenses
33,007
33,007
36,495
51,681
26,835
Operating income or loss
-24,733
-24,733
-22,520
-49,211
-26,447
Total other income/expenses net
-178
-178
-4,121
5,939
3,484
Income before tax
-23,282
-23,282
-25,812
-43,270
-21,924
Income tax expense
-1,803
-1,803
541
0
-1,239
Income from continuing operations
-21,479
-21,479
-26,353
-43,270
-20,685
Net income
-21,486
-21,486
-26,273
-43,019
-20,649
Net income available to common shareholders
-21,486
-21,486
-26,273
-43,019
-20,649
Basic EPS
-0.13
-
-0.15
-0.26
-0.14
Diluted EPS
-0.13
-
-0.15
-0.26
-0.14
Basic average shares
171,411
-
169,792
164,502
150,044
Diluted average shares
171,411
-
169,792
164,502
150,044